featured
Hemodynamic Effects of Empagliflozin in Patients With Type 2 Diabetes at High Cardiovascular Risk
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Diabetes
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Randomized Controlled Trial of the Hemodynamic Effects of Empagliflozin in Patients With Type 2 Diabetes at High Cardiovascular Risk: The SIMPLE Trial
Diabetes 2022 Apr 01;71(4)812-820, E Wolsk, M Jürgens, M Schou, M Ersbøll, P Hasbak, A Kjær, B Zerahn, NH Brandt, PH Gæde, P Rossing, J Faber, SE Inzucchi, CM Kistorp, F GustafssonFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.